Still Hungry on Mounjaro 10mg — Why It Happens and What to Do

You have been on 10mg for three weeks and hunger is creeping back, what is happening

Picture this: the first few weeks at 10mg felt different. Portions naturally shrank. The 4pm reach-for-something urge faded. Then, somewhere in week three, appetite starts edging back in. The biscuits feel tempting again. You are not imagining it, and you are not failing.

Tirzepatide works partly by slowing how quickly food moves through your stomach and partly by acting on hunger-signalling pathways in the brain. Both effects are real, but neither is a permanent ceiling at any given dose. The body is good at adapting. Over several weeks at a steady dose, gastric emptying can partly re-normalise, and some of the central appetite suppression becomes a new background rather than a novel intervention. This is sometimes described as tachyphylaxis (a gradual blunting of response) and it is well documented with GLP-1 class medicines. It does not mean the medicine has stopped working; it means your body has begun to calibrate around it.

The NHS patient information for tirzepatide explains how the medicine acts on two gut-hormone pathways, and understanding those mechanisms helps make sense of why the effect can feel uneven over a four-week pen cycle.

At 10mg you are also two doses from the licensed maximum. The 12.5mg and 15mg steps exist precisely because many people need them. Feeling hungry at 10mg is not an unusual problem; it is often the expected prompt for a clinical conversation about whether to continue titrating.

The wear-off window and protein: two practical angles most people overlook

A question our prescribers hear most weeks is some version of: 'I feel fine on days one and two but by day six I am starving again.' This is the wear-off window. Tirzepatide is a once-weekly injection, but its plasma concentration peaks in the first 48 hours and declines steadily toward injection day. For some people, that decline is clinically noticeable. Hunger returns not because the medicine has failed but because blood levels are lower.

There is not a direct fix for this within the current dosing schedule, that is weekly by design. What can help is timing. Injecting consistently on the same day and at a similar time each week minimises the trough as much as possible. If the hungry days are falling on a Friday and weekend, moving injection day to a Wednesday or Thursday (with prescriber agreement) can shift the trough to less socially challenging days.

Protein adequacy is the other underappreciated factor. Tirzepatide reduces overall food intake, and people on reduced-calorie eating often inadvertently cut protein proportionally. Protein is the most satiating macronutrient; if your meals are lower in protein than before you started, hunger will be louder regardless of what the medicine is doing. Aim to keep protein prominent at each meal (your prescriber or a dietitian can help with practical targets) rather than simply eating less of everything.

People who find that hunger became more manageable when they moved from a lower dose sometimes ask whether the same pattern repeats at 12.5mg; the honest answer is that it can, though the degree typically lessens as dose increases.

When hunger on 10mg is actually a sign to review the whole plan

Not all hunger at 10mg is pharmacological. Some of it is behavioural and environmental, and that matters because pushing to a higher dose will not solve a problem the dose did not create.

Ultra-processed foods are particularly relevant here. They are engineered to override satiety signals, and that applies whether or not you are on tirzepatide. If the foods that feel most tempting are highly palatable, energy-dense and low in fibre, the hunger you are experiencing may be more about reward signalling than genuine caloric need. That is not a moral judgement; it is neuroscience. Tirzepatide blunts appetite effectively for many foods, but the pull of highly palatable options is partially separate from the hunger mechanisms the medicine targets.

Stress and sleep are two other variables that directly affect ghrelin, the hormone most associated with hunger, and neither is touched by tirzepatide. Poor sleep in particular raises ghrelin measurably and reduces leptin, which means a bad week of sleep can make 10mg feel like it is doing nothing.

If you are still hungry on Mounjaro 10mg and weight loss has also plateaued, that combination is worth discussing with a prescriber rather than waiting it out. The NICE appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if 5% weight loss has not been achieved by six months on the highest tolerated dose, which means ongoing lack of response is something the clinical evidence already anticipates and plans for. You can read more about how the overall treatment journey fits together on our tirzepatide treatment guide.

Some people at this point consider whether the 10mg dose is genuinely their highest tolerated dose or whether they moved to it quickly enough to fully assess the 7.5mg step. That is a different question, one for the prescriber, not something to self-manage. If you are weighing that kind of decision, our page on hunger at 7.5mg covers the considerations at the prior step.

The cost of treatment sometimes comes into decisions about whether to continue or titrate upward. For a clear picture of what private Mounjaro treatment involves financially, our treatment page sets out what is included in one transparent price.

If you are near the end of your 10mg pen and wondering how to proceed, speaking to a prescriber is the right next step. Our clinical team is available seven days a week, and you can also review our FAQs for common questions about treatment. For anyone earlier in their journey, the experiences at 5mg and 2.5mg are covered in separate guides, and hunger at the 15mg maintenance dose is a distinct topic if you reach that stage.

Check your eligibility for a clinical assessment with our prescribers via the free consultation, there are no waiting lists, and your answers are reviewed by a GPhC-registered prescriber, not a scoring algorithm.